Prm112 - Incorporation of Anti-Cancer Drugs Adverse Events in Health Economic Opinions of the French National Authority for Health (Has)

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2232
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Use of Budget Impact Analysis (Bia) in Economic Evaluations of Drugs and Medical Devices Submitted to the French National Authority for Health (Has)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Exploring Uncertainty in Economic Evaluation of Medicines: A Review of the First Manufacturers' Submissions to the French National Authority for Health (Has)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Pcn355 - Utility in French Health-Economic Opinions: Key Learnings of a Retrospective Analysis in Oncology Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Methodological Analyses of Budget Impact Models Submitted to the Haute Autorité De Santé (HAS) (French National Authority for Health)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Pmu59 - Are There Any Implicit Guidelines for Including Adverse Events in Cost-Effectiveness Models Intended for French Health Authorities? An Analysis of Efficiency Opinions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Prm34 - French Efficiency Opinions of the Economic and Public Health Committee (Ceesp): Is There an Impact on the Market Access for Innovative Drugs?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Current Status of Health Foods Including Their Interactions With Drugs and Adverse Events

Yakugaku Zasshi
PharmacologyPharmaceutical Science
2018English

Health Care Under French National Health Insurance

Health Affairs
MedicineHealth Policy
1993English

Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy